Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1995 1
1996 2
1997 2
2002 1
2004 1
2006 1
2010 1
2018 1
2020 2
2021 2
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial.
Maruyama S, Kurasawa S, Hayashi T, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T; PREDICT Investigators. Maruyama S, et al. Clin Exp Nephrol. 2023 Sep;27(9):757-766. doi: 10.1007/s10157-023-02362-w. Epub 2023 Jun 8. Clin Exp Nephrol. 2023. PMID: 37289335 Free PMC article. Clinical Trial.
Initiation of renin-angiotensin system inhibitors and first complete remission in patients with primary nephrotic syndrome: a nationwide cohort study.
Shimizu S, Niihata K, Nishiwaki H, Shibagaki Y, Yamamoto R, Nitta K, Tsukamoto T, Uchida S, Takeda A, Okada H, Narita I, Isaka Y, Kurita N; Japan Nephrotic Syndrome Cohort Study Group. Shimizu S, et al. Clin Exp Nephrol. 2023 May;27(5):480-489. doi: 10.1007/s10157-023-02331-3. Epub 2023 Feb 25. Clin Exp Nephrol. 2023. PMID: 36840902
Predictors of early remission of proteinuria in adult patients with minimal change disease: a retrospective cohort study.
Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Takeda A, Uchida S, Tsukamoto T, Tsuruya K, Akai Y, Nitta K, Fukunaga M, Hayashi H, Masutani K, Wada T, Konta T, Katafuchi R, Nishio S, Goto S, Tamai H, Shirasaki A, Shoji T, Nagai K, Nishino T, Yamagata K, Kazama JJ, Hiromura K, Yasuda H, Mizutani M, Naruse T, Hiramatsu T, Morozumi K, Sobajima H, Saka Y, Ishimura E, Ichikawa D, Shigematsu T, Sofue T, Fujimoto S, Ito T, Sato H, Narita I, Isaka Y; JNSCS Investigators. Yamamoto R, et al. Among authors: shirasaki a. Sci Rep. 2022 Jun 13;12(1):9782. doi: 10.1038/s41598-022-13067-7. Sci Rep. 2022. PMID: 35697724 Free PMC article.
Incidence and factors associated with prescribing renin-angiotensin-system inhibitors in adult idiopathic nephrotic syndrome: A nationwide cohort study.
Nishiwaki H, Niihata K, Shimizu S, Shibagaki Y, Yamamoto R, Nitta K, Tsukamoto T, Uchida S, Takeda A, Okada H, Narita I, Isaka Y, Kurita N; Japan Nephrotic Syndrome Cohort Study group. Nishiwaki H, et al. J Clin Hypertens (Greenwich). 2021 May;23(5):999-1007. doi: 10.1111/jch.14224. Epub 2021 Mar 1. J Clin Hypertens (Greenwich). 2021. PMID: 33645883 Free PMC article.
Acute Kidney Injury and Remission of Proteinuria in Minimal Change Disease.
Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Takeda A, Uchida S, Tsukamoto T, Tsuruya K, Akai Y, Nitta K, Fukunaga M, Hayashi H, Shoji T, Masutani K, Konta T, Katafuchi R, Nishio S, Wada T, Goto S, Tamai H, Shirasaki A, Nagai K, Nishino T, Yamagata K, Kazama JJ, Hiromura K, Yasuda H, Sofue T, Fujimoto S, Mizutani M, Naruse T, Hiramatsu T, Morozumi K, Sobajima H, Saka Y, Ishimura E, Ito T, Ichikawa D, Shigematsu T, Sato H, Narita I, Yoshitaka I; Japan Nephrotic Syndrome Cohort Study investigators. Yamamoto R, et al. Among authors: shirasaki a. Kidney Int Rep. 2022 Aug 5;7(10):2283-2288. doi: 10.1016/j.ekir.2022.07.173. eCollection 2022 Oct. Kidney Int Rep. 2022. PMID: 36217532 Free PMC article. No abstract available.
Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study.
Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Takeda A, Tsukamoto T, Uchida S, Tsuruya K, Shoji T, Hayashi H, Akai Y, Fukunaga M, Konta T, Nishio S, Goto S, Tamai H, Nagai K, Katafuchi R, Masutani K, Wada T, Nishino T, Shirasaki A, Sobajima H, Nitta K, Yamagata K, Kazama JJ, Hiromura K, Yasuda H, Mizutani M, Akahori T, Naruse T, Hiramatsu T, Morozumi K, Mimura T, Saka Y, Ishimura E, Hasegawa H, Ichikawa D, Shigematsu T, Sato H, Narita I, Isaka Y; Japan Nephrotic Syndrome Cohort Study investigators. Yamamoto R, et al. Among authors: shirasaki a. J Nephrol. 2022 May;35(4):1135-1144. doi: 10.1007/s40620-022-01279-z. Epub 2022 Apr 2. J Nephrol. 2022. PMID: 35366214
[Uremic dyslipoproteinemia].
Kimura H, Shirasaki A, Suzuki S, Gejyo F. Kimura H, et al. Among authors: shirasaki a. Ryoikibetsu Shokogun Shirizu. 1997;(16 Pt 1):76-9. Ryoikibetsu Shokogun Shirizu. 1997. PMID: 9277689 Review. Japanese. No abstract available.
[Uremic syndrome].
Shirasaki A, Kimura H, Gejyo F. Shirasaki A, et al. Ryoikibetsu Shokogun Shirizu. 1997;(16 Pt 1):38-41. Ryoikibetsu Shokogun Shirizu. 1997. PMID: 9277679 Review. Japanese. No abstract available.
20 results